The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MOF Panel Urges Annual Price Revisions on All Drugs in 2025 Budget Proposal
November 29, 2024
-
REGULATORY Japan to Require Drug Makers to Set Up Legal Post of “Stable Supply Manager”
November 29, 2024
-
REGULATORY Japan Set to Put Up 100 Billion Yen to Support Pharma under Economic Package
November 29, 2024
-
REGULATORY DPP Confirms Plan to Urge 4 Ministers to Scrap Off-Year Price Revisions
November 28, 2024
-
COMMENTARY MOF Stands Pat with Off-Year Revisions despite Change in Politics, Does this Hint at Govt’s Reform Directions?
November 27, 2024
-
BUSINESS Shionogi Chided for Violating Promotion Guidelines with Actair
November 27, 2024
-
REGULATORY Japan Gets Down to the Business of Solving Drug Loss, New Scheme Begins with 78 Meds
November 26, 2024
-
REGULATORY Japan’s New Economic Package Covers Pharma-Related Steps, but Not Repeal of Off-Year Revisions
November 25, 2024
-
REGULATORY Pharma Renews Call for Abolishing Off-Year Revisions, but MHLW Stays Put with Honebuto
November 22, 2024
-
BUSINESS Genmab Japan to Expand into Solid Tumors, Boost Focus on Gyn/Onc: Chief
November 22, 2024
-
REGULATORY 3 Parties Reach Deal on Economic Plan, Off-Year “Abolition” Not Spelled Out
November 21, 2024
-
BUSINESS 25 Japan Drug Makers See 50% Growth in Operating Profit on FX, Unprofitability Re-Pricing
November 20, 2024
-
REGULATORY DPP Leader Poised to Urge 4 Ministers to Abolish Off-Year Revisions
November 20, 2024
-
ORGANIZATION Chuikyo Payer Rep Touts Necessity of FY2025 Off-Year Price Revision
November 19, 2024
-
REGULATORY Qalsody, Zepbound, Zeposia Up for Advisory Panel Review on Dec. 2
November 19, 2024
-
REGULATORY Pediatric Forms of Jakavi, More Drugs to Get Listing; Eylea Biosimilar Not on Roster
November 19, 2024
-
REGULATORY DPP Prods Ruling Camp to Be More Specific on Off-Year Revision in Economic Plan
November 19, 2024
-
BUSINESS Pfizer Japan Taps COO Hiroo Igarashi as New Skipper
November 18, 2024
-
ORGANIZATION Japan, US, Europe Trade Groups Urge Ishiba Govt to Scrap Off-Year Revisions
November 18, 2024
-
BUSINESS MSD Files Silgard 9 for Male Use in Japan
November 18, 2024
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…